Genesis Healthcare - GEN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $25.60
  • Forecasted Upside: 19.51%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$21.42
▼ -0.08 (-0.37%)
Get New Genesis Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GEN

Analyst Price Target is $25.60
▲ +19.51% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Genesis Healthcare in the last 3 months. The average price target is $25.60, with a high forecast of $28.00 and a low forecast of $23.00. The average price target represents a 19.51% upside from the last price of $21.42.

This chart shows the closing price for GEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Genesis Healthcare. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024Morgan StanleyLower TargetOverweight ➝ Overweight$30.00 ➝ $28.00N/A
2/2/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$25.00N/A
1/29/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$28.00 ➝ $30.00N/A
11/21/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$23.00 ➝ $26.00N/A
11/16/2023Bank of AmericaInitiated CoverageBuy$25.00N/A
11/8/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$21.00 ➝ $22.00N/A
8/4/2023BarclaysBoost TargetOverweight ➝ Overweight$22.00 ➝ $23.00N/A
5/19/2023Evercore ISIInitiated CoverageOutperform$27.00N/A
5/12/2023Royal Bank of CanadaLower Target$26.00 ➝ $21.00N/A
5/12/2023BarclaysLower Target$24.00 ➝ $22.00N/A
4/13/2023BarclaysLower TargetOverweight$29.00 ➝ $24.00N/A
1/25/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform$0.57High
11/11/2020Credit Suisse GroupLower TargetNeutral$0.75 ➝ $0.57Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/2/2023
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2023
  • 5 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
10/1/2023
  • 6 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
10/31/2023
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/30/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
1/29/2024
  • 12 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 12 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Genesis Healthcare logo
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Read More

Today's Range

Now: $21.42
Low: $21.36
High: $21.68

50 Day Range

MA: $0.41
Low: $0.18
High: $0.60

52 Week Range

Now: $21.42
Low: $0.40
High: $1.37

Volume

2,457,576 shs

Average Volume

4,100,771 shs

Market Capitalization

$13.69 billion

P/E Ratio

23.80

Dividend Yield

3.05%

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Genesis Healthcare?

The following Wall Street research analysts have issued reports on Genesis Healthcare in the last twelve months: Bank of America Co., Barclays PLC, Evercore ISI, Morgan Stanley, Royal Bank of Canada, StockNews.com, and TheStreet.
View the latest analyst ratings for GEN.

What is the current price target for Genesis Healthcare?

5 Wall Street analysts have set twelve-month price targets for Genesis Healthcare in the last year. Their average twelve-month price target is $25.60, suggesting a possible upside of 19.5%. Morgan Stanley has the highest price target set, predicting GEN will reach $28.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $23.00 for Genesis Healthcare in the next year.
View the latest price targets for GEN.

What is the current consensus analyst rating for Genesis Healthcare?

Genesis Healthcare currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GEN.

What other companies compete with Genesis Healthcare?

Other companies that are similar to Genesis Healthcare include UiPath, Elastic, Procore Technologies, DocuSign and Confluent. Learn More about companies similar to Genesis Healthcare.

How do I contact Genesis Healthcare's investor relations team?

Genesis Healthcare's physical mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company's listed phone number is 610-444-6350 and its investor relations email address is [email protected]. The official website for Genesis Healthcare is www.genesishcc.com. Learn More about contacing Genesis Healthcare investor relations.